Antineoplastics Antineoplastics| Class | Generic name | ATC | KEGG | Products (USA) | Products (Japan) | Indications (USA) | |
| Molecularly targeted agent | Monoclonal antibody | Rituximab | L01XC02 | D02994 | RITUXAN | RITUXAN | CD20-positive non–Hodgkin's lymphoma Chronic lymphocytic leukemia Rheumatoid arthritis Granulomatosis with polyangiitis (Wegener's granulomatosis) and microscopic polyangiitis |
| Trastuzumab | L01XC03 | D03257 | HERCEPTIN | HERCEPTIN | HER2-overexpressing adjuvant breast cancer HER2-overexpressing metastatic breast cancer HER2-overexpressing metastatic gastric cancer |
||
| L01XC14 | D09980 | KADCYLA | KADCYLA | HER2-positive metastatic breast cancer | |||
| Gemtuzumab | L01XC05 | D03259 | MYLOTARG | ||||
| Cetuximab | L01XC06 | D03455 | ERBITUX | ERBITUX | Squamous cell carcinoma of the head and neck K-Ras mutation-negative, EGFR-expressing colorectal cancer |
||
| Bevacizumab | L01XC07 | D06409 | AVASTIN | AVASTIN | Metastatic colorectal cancer Non-squamous non–small cell lung cancer Glioblastoma Metastatic renal cell carcinoma Persistent, recurrent, or metastatic carcinoma of the cervix Platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer |
||
| Panitumumab | L01XC08 | D05350 | VECTIBIX | VECTIBIX | K-Ras mutation negative metastatic colorectal cancer | ||
| Ofatumumab | L01XC10 | D09314 | ARZERRA | ARZERRA | Previously untreated chronic lymphocytic leukemia Refractory chronic lymphocytic leukemia |
||
| Ipilimumab | L01XC11 | D04603 | YERVOY | YERVOY | Unresectable or metastatic melanoma | ||
| Brentuximab | L01XC12 | D09587 | ADCETRIS | ADCETRIS | Hodgkin lymphoma Systemic anaplastic large cell lymphoma |
||
| Pertuzumab | L01XC13 | D05446 | PERJETA | PERJETA | HER2-positive metastatic breast cancer Neoadjuvant treatment of HER2-positive, locally advanced, inflammatory, or early stage breast cancer |
||
| Obinutuzumab | L01XC15 | D09321 | GAZYVA | Previously untreated chronic lymphocytic leukemia | |||
| Dinutuximab | L01XC16 | D10559 | UNITUXIN | Pediatric high-risk neuroblastoma | |||
| Nivolumab | L01XC17 | D10316 | OPDIVO | OPDIVO | Unresectable or metastatic melanoma | ||
| Pembrolizumab | L01XC18 | D10574 | KEYTRUDA | KEYTRUDA | Unresectable or metastatic melanoma with BRAF V600E mutation | ||
| Blinatumomab | L01XC19 | D09325 | BLINCYTO | Philadelphia chromosome negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia | |||
| Ramucirumab | L01XC21 | D09371 | CYRAMZA | CYRAMZA | Gastric cancer Non-small cell lung cancer |
||
| Necitumumab | L01XC22 | D10018 | PORTRAZZA | Squamous non-small cell lung cancer (NSCLC) | |||
| Alemtuzumab | L04AA34 | D02802 | CAMPATH | MABCAMPATH | B-cell chronic lymphocytic leukemia | ||
| Ibritumomab | V10XX02 | D04489 | ZEVALIN | ZEVALIN | Relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma Previously untreated follicular non-Hodgkin's lymphoma |
||
| Elotuzumab | D09337 | EMPLICITI | EMPLICITI | Multiple myeloma | |||
| Mogamulizumab | D09761 | POTELIGEO | |||||
| Atezolizumab | D10773 | TECENTRIQ | Locally advanced or metastatic urothelial carcinoma | ||||
| Olaratumab | D09939 | LARTRUVO | Soft tissue sarcoma | ||||
| Tyrosine kinase inhibitor | Imatinib | L01XE01 | D01441 | GLEEVEC | GLIVEC | Philadelphia chromosome positive chronic myeloid leukemia Philadelphia chromosome positive acute lymphoblastic leukemia Myelodysplastic/myeloproliferative diseases associated with PDGFR gene rearrangements Aggressive systemic mastocytosis without c-Kit mutation D816V Hypereosinophilic syndrome and/or chronic eosinophilic leukemia with FIP1L1-PDGFRα fusion kinase Unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors |
|
| Gefitinib | L01XE02 | D01977 | IRESSA | IRESSA | Locally advanced or metastatic non-small cell lung cancer | ||
| Erlotinib | L01XE03 | D04023 | TARCEVA | TARCEVA | Metastatic non-small cell lung cancer Locally advanced, unresectable or metastatic pancreatic cancer |
||
| Sunitinib | L01XE04 | D06402 | SUTENT | SUTENT | Gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate Advanced renal cell carcinoma Progressive, well-differentiated pancreatic neuroendocrine tumors |
||
| Sorafenib | L01XE05 | D06272 | NEXAVAR | NEXAVAR | Unresectable hepatocellular carcinoma Advanced renal cell carcinoma Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma |
||
| Dasatinib | L01XE06 | D06414 | SPRYCEL | SPRYCEL | Philadelphia chromosome-positive chronic myeloid leukemia Chronic, accelerated, or myeloid or lymphoid blast phase Philadelphia chromosome-positive chronic myeloid leukemia Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. |
||
| Lapatinib | L01XE07 | D04024 | TYKERB | TYKERB | HER2-overexpressing advanced or metastatic breast cancer | ||
| Nilotinib | L01XE08 | D06413 | TASIGNA | TASIGNA | Philadelphia chromosome positive chronic myeloid leukemia |
||
| Pazopanib | L01XE11 | D05380 | VOTRIENT | VOTRIENT | Advanced renal cell carcinoma Advanced soft tissue sarcoma |
||
| Vandetanib | L01XE12 | D06407 | CAPRELSA | CAPRELSA | Symptomatic or progressive medullary thyroid cancer | ||
| Afatinib | L01XE13 | D09733 | GILOTRIF | GILOTRIF | Metastatic non-small cell lung cancer with EGFR exon 19 deletion or exon 21 (L858R) substitution mutation | ||
| Bosutinib | L01XE14 | D09728 | BOSULIF | BOSULIF | Chronic, accelerated, or blast phase Philadelphia chromosome-positive chronic myelogenous leukemia | ||
| Crizotinib | L01XE16 | D09731 | XALKORI | XALKORI | ALK-positive metastatic non-small cell lung cancer | ||
| Axitinib | L01XE17 | D03218 | INLYTA | INLYTA | Advanced renal cell carcinoma | ||
| Ruxolitinib | L01XE18 | D09960 | JAKAFI | JAKAVI | Intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis Polycythemia vera |
||
| Regorafenib | L01XE21 | D10137 | STIVARGA | STIVARGA | Metastatic colorectal cancer Locally advanced, unresectable or metastatic gastrointestinal stromal tumor |
||
| Ponatinib | L01XE24 | D09951 | ICLUSIG | ICLUSIG | T315I-positive chronic myeloid leukemia T315I-positive Philadelphia chromosome positive acute lymphoblastic leukemia |
||
| Cabozantinib | L01XE26 | D10095 | COMETRIQ | Progressive, metastatic medullary thyroid cancer | |||
| Ibrutinib | L01XE27 | D10223 | IMBRUVICA | IMBRUVICA | Mantle cell lymphoma Chronic lymphocytic leukemia Chronic lymphocytic leukemia with 17p deletion Waldenström's macroglobulinemia |
||
| Ceritinib | L01XE28 | D10551 | ZYKADIA | ZYKADIA | ALK-positive metastatic non-small cell lung cancer | ||
| Lenvatinib | L01XE29 | D09920 | LENVIMA | LENVIMA | Locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer | ||
| Alectinib | D10450 | ALECENSA | ALECENSA | ALK-positive metastatic non-small cell lung cancer (NSCLC) | |||
| Osimertinib | D10766 | TAGRISSO | TAGRISSO | metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC) | |||
| mTOR kinase inhibitor | Temsirolimus | L01XE09 | D06068 | TORISEL | TORISEL | Advanced renal cell carcinoma | |
| Everolimus | L01XE10 L04AA18 | D02714 | AFINITOR | AFINITOR | Postmenopausal advanced hormone receptor-positive, HER2-negative breast cancer Progressive neuroendocrine tumors of pancreatic origin Advanced renal cell carcinoma Renal angiomyolipoma and tuberous sclerosis complex Subependymal giant cell astrocytoma |
||
| Other kinase inhibitor | Vemurafenib | L01XE15 | D09996 | ZELBORAF | ZELBORAF | Unresectable or metastatic melanoma with BRAF V600E mutation | |
| Dabrafenib | L01XE23 | D10104 | TAFINLAR | TAFINLAR | Unresectable or metastatic melanoma with BRAF V600E or V600K mutation | ||
| Trametinib | L01XE25 | D10176 | MEKINIST | MEKINIST | Unresectable or metastatic melanoma with BRAF V600E or V600K mutation | ||
| Idelalisib | L01XX47 | D10560 | ZYDELIG | Relapsed chronic lymphocytic leukemia Relapsed follicular B-cell non-Hodgkin lymphoma Relapsed small lymphocytic lymphoma |
|||
| Palbociclib | D10372 | IBRANCE | Postmenopausal, ER-positive, HER2-negative advanced breast cancer | ||||
| Cobimetinib | D10615 | COTELLIC | Unresectable or metastatic melanoma with a BRAF V600E or V600K mutation | ||||
| Proteasome inhibitor | Bortezomib | L01XX32 | D03150 | VELCADE | VELCADE | Multiple myeloma Mantle cell lymphoma |
|
| Carfilzomib | L01XX45 | D08880 | KYPROLIS | KYPROLIS | Multiple myeloma | ||
| Ixazomib | L01XX50 | D10131 | NINLARO | Multiple myeloma | |||
| Retinoic acid receptor agonist | Tretinoin | L01XX14 | D00094 | TRETINOIN | VESANOID | Acute promyelocytic leukemia with t(15;17) translocation and/or PML/RARα | |
| Alitretinoin | L01XX22 | D02815 | PANRETIN | AIDS-related Kaposi's sarcoma | |||
| Bexarotene | L01XX25 | D03106 | TARGRETIN | TARGRETIN | Cutaneous T-cell lymphoma | ||
| Tamibarotene | D01418 | AMNOLAKE | |||||
| Smoothened (SMO) antagonist | Vismodegib | L01XX43 | D09992 | ERIVEDGE | Metastatic or locally advanced basal cell carcinoma | ||
| VEGF inhibitor | Aflibercept | L01XX44 | D09574 | ZALTRAP | Metastatic colorectal cancer | ||
| PARP inhibitor | Olaparib | D09730 | LYNPARZA | Advanced ovarian cancer with gBRCA mutation | |||
| Hormone and hormone antagonist | Androgen | Fluoxymesterone | G03BA01 | D00327 | ANDROXY | Primary hypogonadism (congenital or acquired) Hypogonadotropic hypogonadism (congenital or acquired) Delayed puberty Metastatic mammary cancer |
|
| Androgen antagonist | Flutamide | L02BB01 | D00586 | FLUTAMIDE | ODYNE | Locally confined stage B2-C and stage D2 metastatic carcinoma of the prostate | |
| Nilutamide | L02BB02 | D00965 | NILANDRON | Metastatic prostate cancer (stage D2) | |||
| Bicalutamide | L02BB03 | D00961 | CASODEX | CASODEX | Stage D2 metastatic carcinoma of the prostate | ||
| Enzalutamide | L02BB04 | D10218 | XTANDI | XTANDI | Metastatic castration-resistant prostate cancer | ||
| Estrogen | Ethinylestradiol | G03CA01 L02AA03 | D00554 | PROSEXOL | |||
| Estrogen antagonist | Tamoxifen | L02BA01 | D00966 | SOLTAMOX | NOLVADEX | Breast cancer | |
| Toremifene | L02BA02 | D00967 | FARESTON | FARESTON | Postmenopausal estrogen-receptor positive metastatic breast cancer | ||
| Fulvestrant | L02BA03 | D01161 | FASLODEX | FASLODEX | Postmenopausal hormone receptor positive metastatic breast cancer | ||
| Gonadotropin-releasing hormone agonist | Leuprorelin | L02AE02 | D00989 | LUPRON DEPOT ELIGARD |
LEUPLIN | Advanced prostatic cancer | |
| Goserelin | L02AE03 | D00573 | ZOLADEX | ZOLADEX | Locally confined stage T2b-T4 (stage B2-C) carcinoma of the prostate Advanced carcinoma of the prostate |
||
| Triptorelin | L02AE04 | D06248 | TRELSTAR | Advanced prostate cancer | |||
| Aromatase inhibitor | Anastrozole | L02BG03 | D00960 | ARIMIDEX | ARIMIDEX | Postmenopausal, hormone receptor-positive early breast cancer | |
| Letrozole | L02BG04 | D00964 | FEMARA | FEMARA | Postmenopausal hormone receptor positive early breast cancer | ||
| Exemestane | L02BG06 | D00963 | AROMASIN | AROMASIN | Postmenopausal estrogen-receptor positive early breast cancer | ||
| Corticosteroid | Prednisone | A07EA03 H02AB07 | D00473 | RAYOS | (Indications for neoplastic conditions only) Acute leukemia Aggressive lymphomas |
||
| Polypeptide hormone release suppression | Octreotide | H01CB02 | D06495 | SANDOSTATIN | Acromegaly Metastatic carcinoid tumors Vasoactive intestinal peptide tumors |
||
| Progestin | Medroxyprogesterone | G03AC06 G03DA02 L02AB02 | D00951 | DEPO-PROVERA | HYSRON PROVERA |
Inoperable, recurrent, and metastatic endometrial or renal carcinoma | |
| Other hormone antagonist | Degarelix | L02BX02 | D09400 | FIRMAGON | Advanced prostate cancer | ||
| Abiraterone | L02BX03 | D09701 | ZYTIGA | ZYTIGA | Metastatic castration-resistant prostate cancer | ||
| Biologic response modifier (BRM) | Interferone | Interferon alfa natural | L03AB01 | D03305 | OIF SUMIFERON |
||
| Interferon beta natural | L03AB02 | D03304 | FERON | ||||
| Interferon gamma | L03AB03 | D00747 D03357 |
ACTIMMUNE | IMUNOMAX | Severe, malignant osteopetrosis | ||
| Interferon alfa-2b | L03AB05 | D02745 | INTRON A | INTRON A | Hairy cell leukemia Follicular lymphoma Condylomata acuminata AIDS-related Kaposi's sarcoma Chronic hepatitis C |
||
| Interleukin | Aldesleukin | L03AC01 | D00748 | PROLEUKIN | Metastatic renal cell carcinoma Metastatic melanoma |
||
| Oprelvekin | L03AC02 | D05266 | NEUMEGA | Nonmyeloid malignancies | |||
| Denileukin diftitox | L01XX29 | D03682 | ONTAK | CD25-expressing persistent or recurrent cutaneous T-cell lymphoma | |||
| Colony stimulating factor | Filgrastim | L03AA02 | D03235 | NEUPOGEN | GRAN | Nonmyeloid malignancies Acute myeloid leukemia |
|
| Sargramostim | L03AA09 | D05803 | LEUKINE | Acute myelogenous leukemia | |||
| Lenograstim | L03AA10 | D03247 | NEUTROGIN | ||||
| Pegfilgrastim | L03AA13 | D06889 | NEULASTA | G-LASTA | Non‑myeloid malignancies | ||
| Hematopoietic stem cell mobilizer | Plerixafor | L03AX16 | D08971 | MOZOBIL | Non-Hodgkin’s lymphoma Multiple myeloma |
||
| Nonspecific immunomodulation | Thalidomide | L04AX02 | D00754 | THALOMID | THALED | 1.1 Multiple Myeloma 1.2 Erythema Nodosum Leprosum | |
| Lenalidomide | L04AX04 | D04687 D09813 |
REVLIMID | REVLIMID | Multiple myeloma Myelodysplastic syndromes Mantle cell lymphoma |
||
| Pomalidomide | L04AX06 | D08976 | POMALYST | POMALYST | Multiple myeloma | ||
| Alkylating agent | Nitrogen mustard analog | Cyclophosphamide | L01AA01 | D00287 | CYCLOPHOSPHAMIDE | ENDOXAN | Malignant lymphomas (stages III and IV), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma Multiple myeloma Leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) Mycosis fungoides (advanced disease) Neuroblastoma (disseminated disease) Adenocarcinoma of the ovary Retinoblastoma Carcinoma of the breast |
| Chlorambucil | L01AA02 | D00266 | LEUKERAN | Chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, Hodgkin’s disease | |||
| Melphalan | L01AA03 | D00369 D08173 |
ALKERAN | ALKERAN | Multiple myeloma Non-resectable epithelial carcinoma of the ovary |
||
| Chlormethine | L01AA05 | D07671 D04872 |
VALCHLOR MUSTARGEN |
Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma | |||
| Ifosfamide | L01AA06 | D00343 | IFOSFAMIDE | IFOMIDE | Germ cell testicular cancer | ||
| Bendamustine | L01AA09 | D07085 | TREANDA | TREAKISYM | Chronic lymphocytic leukemia Non-Hodgkin lymphoma |
||
| Estramustine | L01XX11 | D02398 D06397 |
EMCYT | ESTRACYT | Metastatic and/or progressive carcinoma of the prostate | ||
| Alkyl sulfonate | Busulfan | L01AB01 | D00248 | BUSULFEX MYLERAN |
BUSULFEX | Chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia | |
| Nitrosourea | Carmustine | L01AD01 | D00254 | GLIADEL | GLIADEL | High-grade malignant glioma | |
| Lomustine | L01AD02 | D00363 | CEENU | Brain tumors (both primary and metastatic) | |||
| Streptozocin | L01AD04 | D05932 | ZANOSAR | ZANOSAR | Metastatic islet cell carcinoma of the pancreas | ||
| Nimustine | L01AD06 | D01059 | NIDRAN | ||||
| Ranimustine | L01AD07 | D01760 | CYMERIN | ||||
| Triazene | Temozolomide | L01AX03 | D06067 | TEMODAR | TEMODAL | Glioblastoma multiforme Refractory anaplastic astrocytoma |
|
| Dacarbazine | L01AX04 | D00288 | DACARBAZINE | DACARBAZINE | Metastatic malignant melanoma | ||
| Platinum compound | Cisplatin | L01XA01 | D00275 | PLANTINOL | BRIPLATIN RANDA |
Metastatic testicular tumors Metastatic ovarian tumors Advanced bladder cancer |
|
| Carboplatin | L01XA02 | D01363 | CARBOPLATIN | PARAPLATIN | Advanced ovarian carcinoma | ||
| Oxaliplatin | L01XA03 | D01790 | OXALIPLATIN | ELPLAT | Stage III colon cancer Advanced colorectal cancer |
||
| Nedaplatin | D01416 | AQUPLA | |||||
| Antimetabolite | Folic acid analog | Methotrexate | L01BA01 L04AX03 | D00142 D02115 |
METHOTREXATE RHEUMATREX |
METHOTREXATE | Gestational choriocarcinoma, chorio-adenoma destruens, hydatidiform mole Breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), lung cancer (particularly squamous cell and small cell types) |
| Pemetrexed | L01BA04 | D06503 D03828 |
ALIMTA | ALIMTA | Nonsquamous non-small cell lung cancer | ||
| Pralatrexate | L01BA05 | D05589 | FOLOTYN | Relapsed or refractory peripheral T-cell lymphoma | |||
| Purine analog | Mercaptopurine | L01BB02 | D00161 | PURINETHOL | LEUKERIN | Acute lymphatic (lymphocytic, lymphoblastic) leukemia | |
| Thioguanine | L01BB03 | D06109 | TABLOID | Acute nonlymphocytic leukemias | |||
| Cladribine | L01BB04 | D01370 | CLADRIBINE | LEUSTATIN | Active hairy cell leukemia | ||
| Fludarabine | L01BB05 | D01907 | OFORTA | FLUDARA | B-cell chronic lymphocytic leukemia | ||
| Clofarabine | L01BB06 | D03546 | CLOLAR | EVOLTRA | Relapsed or refractory acute lymphoblastic leukemia | ||
| Nelarabine | L01BB07 | D05134 | ARRANON | ARRANON G | T-cell acute lymphoblastic leukemia, T-cell lymphoblastic lymphoma | ||
| Pentostatin | L01XX08 | D00155 | NIPENT | COFORIN | Hairy cell leukemia | ||
| Pyrimidine analog | Cytarabine | L01BC01 | D00168 D03046 |
DEPOCYT | CYLOCIDE STARASID |
Lymphomatous meningitis | |
| Fluorouracil | L01BC02 | D00584 | FLUOROURACIL | 5-FU | Multiple actinic or solar keratoses | ||
| Tegafur | L01BC03 | D01244 | FUTRAFUL | ||||
| Gemcitabine | L01BC05 | D01155 | GEMZAR | GEMZAR | Advanced ovarian cancer Metastatic breast cancer Inoperable, locally advanced (stage IIIA or IIIB), or metastatic (stage IV) non-small cell lung cancer Locally advanced (nonresectable stage II or stage III) or metastatic (stage IV) adenocarcinoma of the pancreas |
||
| Capecitabine | L01BC06 | D01223 | XELODA | XELODA | Dukes' C colon cancer Metastatic colorectal carcinoma Metastatic breast cancer |
||
| Azacitidine | L01BC07 | D03021 | VIDAZA | VIDAZA | Myelodysplastic syndromes | ||
| Decitabine | L01BC08 | D03665 | DACOGEN | Myelodysplastic syndromes | |||
| Floxuridine | D04197 | FLOXURIDINE | Gastrointestinal adenocarcinoma metastatic to the liver | ||||
| Tegafur, mixt | L01BC53 | D02131 | UFT | ||||
| D06399 | TS-1 | ||||||
| Trifluridine, mixt | L01BC59 | D10526 | LONSURF | ||||
| Enocitabine | D01633 | SUNRABIN | |||||
| Doxifluridine | D01309 | FURTULON | |||||
| Natural product | Antibiotic | Actinomycin | L01DA01 | D00214 | COSMEGEN | COSMEGEN | Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma, metastatic nonseminomatous testicular cancer Gestational trophoblastic neoplasia Locally recurrent or locoregional solid malignancies |
| Doxorubicin | L01DB01 | D01275 | DOXIL | ADRIACIN DOXIL |
Ovarian cancer AIDS-related Kaposi's sarcoma Multiple myeloma |
||
| Daunorubicin | L01DB02 | D01264 | DAUNORUBICIN HYDROCHLORIDE | DAUNOMYCIN | Acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) | ||
| Epirubicin | L01DB03 | D02214 | ELLENCE | FARMORUBICIN | Axillary node tumor involvement | ||
| Aclarubicin | L01DB04 | D01911 | ACLACINON | ||||
| Idarubicin | L01DB06 | D01747 | IDAMYCIN PFS | IDAMYCIN | Acute myeloid leukemia | ||
| Mitoxantrone | L01DB07 | D02166 | MITOXANTRONE | NOVANTRON | Advanced hormone-refractory prostate cancer Acute nonlymphocytic (myelogenous, promyelocytic, monocytic, and erythroid) leukemia |
||
| Pirarubicin | L01DB08 | D08386 | THERARUBICIN PINORUBIN |
||||
| Valrubicin | L01DB09 | D02697 | VALSTAR | BCG-refractory carcinoma in situ of the urinary bladder | |||
| Amrubicin | L01DB10 | D07100 | CALSED | ||||
| Bleomycin | L01DC01 | D02177 D03229 |
BLEOMYCIN | BLEO | Squamous cell carcinoma Lymphomas Testicular carcinoma Malignant pleural effusion |
||
| Mitomycin | L01DC03 | D00208 | MITOMYCIN | MITOMYCIN | Disseminated adenocarcinoma of the stomach or pancreas | ||
| Ixabepilone | L01DC04 | D04645 | IXEMPRA | Locally advanced breast cancer | |||
| Peplomycin | D02063 | PEPLEO | |||||
| Microtubule polymer stabilizer | Paclitaxel | L01CD01 | D00491 | ABRAXANE | TAXOL ABRAXANE |
Metastatic breast cancer Locally advanced or metastatic non-small cell lung cancer Metastatic adenocarcinoma of the pancreas |
|
| Docetaxel | L01CD02 | D07866 D02165 |
DOCETAXEL | DOCETAXEL TAXOTERE |
Locally advanced or metastatic breast cancer Locally advanced or metastatic non-small cell lung cancer Androgen independent (hormone refractory) metastatic prostate cancer Advanced gastric adenocarcinoma Locally advanced squamous cell carcinoma of the head and neck |
||
| Cabazitaxel | L01CD04 | D09755 D10452 |
JEVTANA | JEVTANA | Hormone-refractory metastatic prostate cancer | ||
| Mitotic inhibitor | Vinblastine | L01CA01 | D01068 | VINBLASTINE SULFATE | EXAL | Generalized Hodgkin’s disease (stages III and IV) Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) Histiocytic lymphoma Mycosis fungoides (advanced stages) Advanced carcinoma of the testis Kaposi’s sarcoma Letterer-Siwe disease (histiocytosis X) |
|
| Vincristine | L01CA02 | D02197 | MARQIBO | ONCOVIN | Philadelphia chromosome-negative acute lymphoblastic leukemia | ||
| Vindesine | L01CA03 | D01769 | FILDESIN | ||||
| Vinorelbine | L01CA04 | D01935 | NAVELBINE | NAVELBINE | Locally advanced or metastatic non-small cell lung cancer | ||
| Eribulin | L01XX41 | D08914 | HALAVEN | HALAVEN | Metastatic breast cancer | ||
| Topoisomerase I inhibitor | Topotecan | L01XX17 | D02168 | TOPOTECAN | HYCAMTIN | Chemotherapy-sensitive small cell lung cancer Stage IVB, recurrent or persistent carcinoma of the cervix |
|
| Irinotecan | L01XX19 | D01061 | CAMPTOSAR | CAMPTO TOPOTECIN |
Metastatic carcinoma of the colon or rectum | ||
| Topoisomerase II inhibitor | Etoposide | L01CB01 | D00125 | ETOPOSIDE | PESID LASTET |
Refractory testicular tumors small cell lung cancer |
|
| D04107 | ETOPOPHOS | Refractory testicular tumors Small cell lung cancer |
|||||
| Teniposide | L01CB02 | D02698 | VUMON | Refractory childhood acute lymphoblastic leukemia | |||
| Sobuzoxane | D01404 | PERAZOLIN | |||||
| Anti-tumor immunostimulation | Picibanil | D08756 | PICIBANIL | ||||
| Other | Trabectedin | L01CX01 | D06199 | YONDELIS | YONDELIS | ||
| Miscellaneous agent | Methylhydrazine | Procarbazine | L01XB01 | D00478 | MATULANE | PROCARBAZINE HYDROCHLORIDE | Stage III and IV Hodgkin's disease |
| Sensitizer used in photodynamic/radiation therapy | Porfimer sodium | L01XD01 | D03327 | PHOTOFRIN | PHOTOFRIN | Completely or partially obstructing esophageal cancer Microinvasive endobronchial non-small-cell lung cancer High-grade dysplasia in Barrett's esophagus |
|
| Aminolevulinic acid | L01XD04 | D02908 | ALAGLIO ALABEL |
||||
| Radiotherapy | Sodium iodide I 131 | V10XA01 | D02259 | HICON | SODIUM IODIDE | Carcinoma of the thyroid | |
| Sodium phosphate P 32 | V10XX01 | D05870 | P32 SODIUM PHOSPHATE | Chronic myelocytic leukemia Chronic lymphocytic leukemia |
|||
| Radium-223 dichloride | V10XX03 | D10398 | XOFIGO | XOFIGO | Castration-resistant prostate cancer | ||
| Bisphosphonate | Pamidronic acid | M05BA03 | D00941 | PAMIDRONATE DISODIUM | AREDIA | Moderate or severe hypercalcemia associated with malignancy Moderate to severe Paget’s disease of bone Osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma |
|
| Zoledronic acid | M05BA08 | D01968 | ZOMETA | ZOMETA | Hypercalcemia of malignancy Multiple myeloma and bone metastases of solid tumors |
||
| Cytoprotector (reactive species antagonist) | Dexrazoxane | V03AF02 | D03730 | SAVENE | SAVENE | ||
| V03AF02 | D07807 | ZINECARD | Cardiomyopathy associated with metastatic breast cancer | ||||
| Amifostine | V03AF05 | D00226 | AMIFOSTINE | Cumulative renal toxicity associated with advanced ovarian cancer | |||
| Somatostatin analog | Octreotide | H01CB02 | D02250 D06495 |
SANDOSTATIN | SANDOSTATIN | Acromegaly Carcinoid tumors Vasoactive intestinal peptide tumors |
|
| Lanreotide | H01CB03 | D04666 | SOMATULINE | Gastroenteropancreatic neuroendocrine tumors | |||
| Substituted melanine | Altretamine | L01XX03 | D02841 | HEXALEN | Persistent or recurrent ovarian cancer | ||
| Substitued urea | Hydroxycarbamide | L01XX05 | D00341 | HYDREA | HYDREA | Melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary | |
| Adrenocortical suppressant | Mitotane | L01XX23 | D00420 | LYSODREN | OPEPRIM | Inoperable adrenal cortical carcinoma of both functional and nonfunctional types | |
| Platelet-reducing agent | Anagrelide | L01XX35 | D02933 D10255 |
AGRYLIN | AGRYLIN | Thrombocythemia, secondary to myeloproliferative neoplasms | |
| Histone deacetylase inhibitor | Vorinostat | L01XX38 | D06320 | ZOLINZA | ZOLINZA | Cutaneous T-cell lymphoma | |
| Panobinostat | L01XX42 | D10019 | FARYDAK | FARYDAK | Multiple myeloma | ||
| Belinostat | L01XX49 | D08870 | BELEODAQ | Relapsed or refractory peripheral T-cell lymphoma | |||
| Other antineoplastic agent | Asparaginase | L01XX02 | D02997 | ERWINAZE | LEUNASE | Acute lymphoblastic leukemia with hypersensitivity to E. coli-derived asparaginase | |
| Pegaspargase | L01XX24 | D05387 | ONCASPAR | Acute lymphoblastic leukemia | |||
| Arsenic trioxide | L01XX27 | D02106 | TRISENOX | TRISENOX | Acute promyelocytic leukemia with t(15;17) translocation or PML/RAR-alpha gene expression | ||
| Romidepsin | L01XX39 | D06637 | ISTODAX | Cutaneous T-cell lymphoma Peripheral T-cell lymphoma |
|||
| Omacetaxine | L01XX40 | D08956 | SYNRIBO | Chronic or accelerated phase chronic myeloid leukemia | |||